Nektar Therapeutics (NKTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nektar Therapeutics (NKTR) has a cash flow conversion efficiency ratio of -0.084x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-75.77 Million) by net assets ($903.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nektar Therapeutics stock valuation for the company's overall valuation and market capitalisation.
Nektar Therapeutics - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Nektar Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nektar Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nektar Therapeutics ranked by their cash flow conversion efficiency. Explore NKTR cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianma Microelectronics Co Ltd
SHE:000050
|
0.018x |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
0.068x |
|
Hanmi Science
KO:008930
|
0.008x |
|
Civitas Resources Inc
NYSE:CIVI
|
0.129x |
|
Aether Industries Limited
NSE:AETHER
|
0.047x |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
0.031x |
|
Sellas Life Sciences Group Inc
NASDAQ:SLS
|
-0.055x |
|
Thule Group AB
ST:THULE
|
0.007x |
Annual Cash Flow Conversion Efficiency for Nektar Therapeutics (1994–2025)
The table below shows the annual cash flow conversion efficiency of Nektar Therapeutics from 1994 to 2025. View NKTR stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $89.83 Million | $-208.51 Million | -2.321x | +19.77% |
| 2024-12-31 | $60.74 Million | $-175.71 Million | -2.893x | -96.74% |
| 2023-12-31 | $130.99 Million | $-192.61 Million | -1.470x | -77.34% |
| 2022-12-31 | $366.64 Million | $-304.01 Million | -0.829x | -36.54% |
| 2021-12-31 | $679.51 Million | $-412.66 Million | -0.607x | -108.83% |
| 2020-12-31 | $1.08 Billion | $-313.29 Million | -0.291x | -24.35% |
| 2019-12-31 | $1.41 Billion | $-328.68 Million | -0.234x | -155.93% |
| 2018-12-31 | $1.72 Billion | $718.21 Million | 0.418x | +145.67% |
| 2017-12-31 | $87.83 Million | $-80.41 Million | -0.916x | +31.05% |
| 2016-12-31 | $88.12 Million | $-117.02 Million | -1.328x | +88.32% |
| 2015-12-31 | $6.43 Million | $-73.08 Million | -11.368x | -190.84% |
| 2014-12-31 | $36.33 Million | $-142.01 Million | -3.909x | -1012.07% |
| 2013-12-31 | $-89.90 Million | $-38.53 Million | 0.429x | +115.53% |
| 2012-12-31 | $47.02 Million | $-129.76 Million | -2.760x | -379.95% |
| 2011-12-31 | $197.81 Million | $-113.74 Million | -0.575x | +6.69% |
| 2010-12-31 | $90.66 Million | $-55.87 Million | -0.616x | -258.75% |
| 2009-12-31 | $102.37 Million | $39.74 Million | 0.388x | +150.64% |
| 2008-12-31 | $190.15 Million | $-145.78 Million | -0.767x | -212.37% |
| 2007-12-31 | $214.44 Million | $146.30 Million | 0.682x | +267.08% |
| 2006-12-31 | $227.06 Million | $-92.72 Million | -0.408x | -71.09% |
| 2005-12-31 | $326.81 Million | $-78.00 Million | -0.239x | -42.74% |
| 2004-12-31 | $467.34 Million | $-78.14 Million | -0.167x | +63.97% |
| 2003-12-31 | $164.19 Million | $-76.20 Million | -0.464x | -27.99% |
| 2002-12-31 | $206.77 Million | $-74.97 Million | -0.363x | -93.04% |
| 2001-12-31 | $270.31 Million | $-50.77 Million | -0.188x | -46.04% |
| 2000-12-31 | $277.88 Million | $-35.74 Million | -0.129x | +27.34% |
| 1999-12-31 | $86.63 Million | $-15.33 Million | -0.177x | -6.70% |
| 1998-12-31 | $115.88 Million | $-19.22 Million | -0.166x | -423.49% |
| 1997-12-31 | $97.09 Million | $4.98 Million | 0.051x | +131.03% |
| 1996-12-31 | $35.10 Million | $-5.80 Million | -0.165x | +37.02% |
| 1995-12-31 | $20.20 Million | $-5.30 Million | -0.262x | -1.01% |
| 1994-12-31 | $15.40 Million | $-4.00 Million | -0.260x | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more